Firefly Neuroscience CEO Jon Olsen to Speak at Global Conference
Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company dedicated to enhancing brain health, has announced that CEO Jon Olsen will present at H.C. Wainwright’s 26th Annual Global Investment Conference. This significant event will showcase groundbreaking developments within the company, including their FDA-510(k) cleared Brain Network Analytics (BNA™) platform.
Key Presentation Insights and Corporate Achievements
During the conference, Mr. Olsen will discuss noteworthy advancements, particularly the recent merger with WaveDancer. His presentation will emphasize Firefly’s dedication to improving healthcare for individuals facing neurological and mental health challenges. The BNA™ platform aims to provide healthcare professionals with objective evaluations of brain activity, aiding in the diagnosis and treatment of various conditions such as depression, dementia, anxiety disorders, concussions, and ADHD.
Details of the H.C. Wainwright Conference
Event: H.C. Wainwright’s 26th Annual Global Investment Conference
Date: September 11, 2024
Time: 1:30 p.m. ET
Location: Lotte New York Palace Hotel, New York City
Speaker: Jon Olsen, CEO
The Future of Brain Health Technologies
Firefly’s BNA™ technology is pioneering in its field, utilizing AI to provide precise diagnostics and treatment evaluations. This innovative platform is built upon a vast database of brain wave tests and clinical data, designed to empower healthcare providers with comprehensive insights into brain functionality. With BNA™, clinicians can make well-informed decisions regarding patient care, tailoring treatment strategies to meet individual needs.
Development and Market Launch of BNA™
For over 15 years, Firefly has been building its extensive database, securing essential IP protections and FDA approvals required for the commercial launch of the BNA™ technology. The Company is now concentrating on forming partnerships with pharmaceutical firms engaged in drug research and clinical trials, as well as collaborating with medical professionals for clinical applications.
Company Overview
Firefly Neuroscience is dedicated to advancing brain health through the use of state-of-the-art AI technologies. The BNA™ platform is distinguished by its innovative combination of machine learning and a comprehensive collection of high-definition longitudinal EEG data from over 17,000 patients with various brain health conditions. This integration enhances both diagnostic precision and therapeutic effectiveness.
The Significance of Accurate Brain Activity Measurement
Accurate measurement of brain activity is essential for guiding treatment decisions in mental health care. The BNA™ platform equips clinicians with thorough analytical tools, enabling them to identify the most appropriate therapies and interventions for their patients effectively.
Contact Information for Investors and Media
For inquiries about one-on-one meetings with Mr. Olsen or Dr. Samer Kaba, Chief Medical Officer, stakeholders can reach out through KCSA Strategic Communications. Investor relations are handled by Valter Pinto at KCSA, who can be contacted at (212) 896-1254. Media inquiries should be directed to Raquel Cona at (516) 779-2630.
Frequently Asked Questions
What is the main focus of Firefly Neuroscience?
Firefly Neuroscience is dedicated to developing AI technologies aimed at enhancing brain health outcomes for patients with neurological and mental disorders.
What topics will Jon Olsen cover at the conference?
Jon Olsen will discuss recent corporate developments, including the merger with WaveDancer and advancements in the FDA-cleared Brain Network Analytics technology.
When will the H.C. Wainwright Conference take place?
The H.C. Wainwright’s 26th Annual Global Investment Conference is set for September 9-11, 2024, with Jon Olsen's presentation scheduled for September 11 at 1:30 p.m. ET.
How does BNA™ technology assist clinicians?
BNA™ technology offers comprehensive insights into brain function, aiding clinicians in diagnosing mental and cognitive disorders and optimizing patient care.
Who should be contacted for investor relations inquiries?
Investors can reach out to Valter Pinto at KCSA Strategic Communications for any inquiries related to the company or to arrange meetings with senior executives.
